Genomictree지노믹트리

Genomictree's shares have fallen sharply over the past year while losses remain deep relative to a small revenue base.

Genomictree is a Korean cancer diagnostics company whose main product is a stool-based colorectal cancer test sold mainly in South Korea. On trailing twelve-month figures to H1 2026 it reported revenue of ₩2.9B against an operating loss of ₩11.7B, and its share price is down about 51% over one year, trading at ₩9,400 near its 52-week low of ₩8,790. The data shows a company with ₩17.5B in cash and no borrowings, but with ongoing cash burn.

What stands out

• Trailing revenue of ₩2.9B is well below 2025 revenue of ₩3.8B and 2022 revenue of ₩29.9B, so sales have been volatile year to year.
• Operating losses have been large every recent year, with a trailing operating margin of about -398% and free cash flow of -₩12.4B.
• The company reports no borrowings and liabilities equal to about 2% of equity, with cash of ₩17.5B, though the data does not give a runway estimate.
• The DCF model in the data gives a fair value of about ₩3,254 per share, well below the ₩9,400 close, but the data does not explain the assumptions behind it and it is not a forecast.
• Recent filings include a half-year report, quarterly report, treasury share sale and several IR events, while the news list is empty.

What to watch

• The next filings on results and cash flow, to see whether revenue recovers and losses narrow from the trailing figures.
• Any further treasury share disposals or insider shareholding changes, given the recent filings in May 2026.
• Progress on the planned bladder, prostate and lung cancer tests and overseas partnerships, which the data does not quantify.